Literature DB >> 24713654

CXCL11-dependent induction of FOXP3-negative regulatory T cells suppresses autoimmune encephalomyelitis.

Yaniv Zohar, Gizi Wildbaum, Rostislav Novak, Andrew L Salzman, Marcus Thelen, Ronen Alon, Yiftah Barsheshet, Christopher L Karp, Nathan Karin.   

Abstract

A single G protein-coupled receptor (GPCR) can activate multiple signaling cascades based on the binding of different ligands. The biological relevance of this feature in immune regulation has not been evaluated. The chemokine-binding GPCR CXCR3 is preferentially expressed on CD4+ T cells, and canonically binds 3 structurally related chemokines: CXCL9, CXCL10, and CXCL11. Here we have shown that CXCL10/CXCR3 interactions drive effector Th1 polarization via STAT1, STAT4, and STAT5 phosphorylation, while CXCL11/CXCR3 binding induces an immunotolerizing state that is characterized by IL-10(hi) (Tr1) and IL-4(hi) (Th2) cells, mediated via p70 kinase/mTOR in STAT3- and STAT6-dependent pathways. CXCL11 binds CXCR3 with a higher affinity than CXCL10, suggesting that CXCL11 has the potential to restrain inflammatory autoimmunity. We generated a CXCL11-Ig fusion molecule and evaluated its use in the EAE model of inflammatory autoimmune disease. Administration of CXCL11-Ig during the first episode of relapsing EAE in SJL/J mice not only led to rapid remission, but also prevented subsequent relapse. Using GFP-expressing effector CD4+ T cells, we observed that successful therapy was associated with reduced accumulation of these cells at the autoimmune site. Finally, we showed that very low doses of CXCL11 rapidly suppress signs of EAE in C57BL/6 mice lacking functional CXCL11.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24713654      PMCID: PMC4001543          DOI: 10.1172/JCI71951

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  69 in total

1.  Targeted overexpression of IL-18 binding protein at the central nervous system overrides flexibility in functional polarization of antigen-specific Th2 cells.

Authors:  Sagie Schif-Zuck; Juergen Westermann; Nir Netzer; Yaniv Zohar; Moran Meiron; Gizi Wildbaum; Nathan Karin
Journal:  J Immunol       Date:  2005-04-01       Impact factor: 5.422

Review 2.  Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self.

Authors:  Shimon Sakaguchi
Journal:  Nat Immunol       Date:  2005-04       Impact factor: 25.606

3.  Phenotypic differences between Th1 and Th17 cells and negative regulation of Th1 cell differentiation by IL-17.

Authors:  Susumu Nakae; Yoichiro Iwakura; Hajime Suto; Stephen J Galli
Journal:  J Leukoc Biol       Date:  2007-02-16       Impact factor: 4.962

4.  Severe disease, unaltered leukocyte migration, and reduced IFN-gamma production in CXCR3-/- mice with experimental autoimmune encephalomyelitis.

Authors:  Liping Liu; Deren Huang; Masaru Matsui; Toby T He; Taofang Hu; Julie Demartino; Bao Lu; Craig Gerard; Richard M Ransohoff
Journal:  J Immunol       Date:  2006-04-01       Impact factor: 5.422

Review 5.  A brief history of T(H)17, the first major revision in the T(H)1/T(H)2 hypothesis of T cell-mediated tissue damage.

Authors:  Lawrence Steinman
Journal:  Nat Med       Date:  2007-02       Impact factor: 53.440

6.  CXCR3 requires tyrosine sulfation for ligand binding and a second extracellular loop arginine residue for ligand-induced chemotaxis.

Authors:  Richard A Colvin; Gabriele S V Campanella; Lindsay A Manice; Andrew D Luster
Journal:  Mol Cell Biol       Date:  2006-08       Impact factor: 4.272

7.  Disrupted cardiac development but normal hematopoiesis in mice deficient in the second CXCL12/SDF-1 receptor, CXCR7.

Authors:  Frederic Sierro; Christine Biben; Laura Martínez-Muñoz; Mario Mellado; Richard M Ransohoff; Meizhang Li; Blanche Woehl; Helen Leung; Joanna Groom; Marcel Batten; Richard P Harvey; Carlos Martínez-A; Charles R Mackay; Fabienne Mackay
Journal:  Proc Natl Acad Sci U S A       Date:  2007-09-05       Impact factor: 11.205

8.  Monocyte emigration from bone marrow during bacterial infection requires signals mediated by chemokine receptor CCR2.

Authors:  Natalya V Serbina; Eric G Pamer
Journal:  Nat Immunol       Date:  2006-02-05       Impact factor: 25.606

9.  IL-12- and IL-23-induced T helper cell subsets: birds of the same feather flock together.

Authors:  Estelle Bettelli; Vijay K Kuchroo
Journal:  J Exp Med       Date:  2005-01-17       Impact factor: 14.307

10.  A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development.

Authors:  Jennifer M Burns; Bretton C Summers; Yu Wang; Anita Melikian; Rob Berahovich; Zhenhua Miao; Mark E T Penfold; Mary Jean Sunshine; Dan R Littman; Calvin J Kuo; Kevin Wei; Brian E McMaster; Kim Wright; Maureen C Howard; Thomas J Schall
Journal:  J Exp Med       Date:  2006-08-28       Impact factor: 14.307

View more
  62 in total

1.  Biased agonists of the chemokine receptor CXCR3 differentially control chemotaxis and inflammation.

Authors:  Jeffrey S Smith; Lowell T Nicholson; Jutamas Suwanpradid; Rachel A Glenn; Nicole M Knape; Priya Alagesan; Jaimee N Gundry; Thomas S Wehrman; Amber Reck Atwater; Michael D Gunn; Amanda S MacLeod; Sudarshan Rajagopal
Journal:  Sci Signal       Date:  2018-11-06       Impact factor: 8.192

2.  Antibody Neutralization of CXCL10 in Vivo Is Dependent on Binding to Free and Not Endothelial-bound Chemokine: IMPLICATIONS FOR THE DESIGN OF A NEW GENERATION OF ANTI-CHEMOKINE THERAPEUTIC ANTIBODIES.

Authors:  Pauline Bonvin; Franck Gueneau; Vanessa Buatois; Maud Charreton-Galby; Stanley Lasch; Marie Messmer; Urs Christen; Andrew D Luster; Zoë Johnson; Walter Ferlin; Marie Kosco-Vilbois; Amanda Proudfoot; Nicolas Fischer
Journal:  J Biol Chem       Date:  2017-01-30       Impact factor: 5.157

3.  Donor interleukin-22 and host type I interferon signaling pathway participate in intestinal graft-versus-host disease via STAT1 activation and CXCL10.

Authors:  B Lamarthée; F Malard; C Gamonet; C Bossard; M Couturier; J-C Renauld; M Mohty; P Saas; B Gaugler
Journal:  Mucosal Immunol       Date:  2015-07-08       Impact factor: 7.313

Review 4.  Type 1 regulatory T cells: a new mechanism of peripheral immune tolerance.

Authors:  Hanyu Zeng; Rong Zhang; Boquan Jin; Lihua Chen
Journal:  Cell Mol Immunol       Date:  2015-06-08       Impact factor: 11.530

5.  Mechanisms of immune tolerance to allergens: role of IL-10 and Tregs.

Authors:  Cezmi A Akdis; Mübeccel Akdis
Journal:  J Clin Invest       Date:  2014-11-03       Impact factor: 14.808

6.  Partial Agonist and Biased Signaling Properties of the Synthetic Enantiomers J113863/UCB35625 at Chemokine Receptors CCR2 and CCR5.

Authors:  Jenny Corbisier; Alexandre Huszagh; Céline Galés; Marc Parmentier; Jean-Yves Springael
Journal:  J Biol Chem       Date:  2016-11-28       Impact factor: 5.157

Review 7.  Promises and limitations of immune cell-based therapies in neurological disorders.

Authors:  Xiaoming Hu; Rehana K Leak; Angus W Thomson; Fang Yu; Yuguo Xia; Lawrence R Wechsler; Jun Chen
Journal:  Nat Rev Neurol       Date:  2018-09       Impact factor: 42.937

8.  Type I Interferon Therapy Limits CNS Autoimmunity by Inhibiting CXCR3-Mediated Trafficking of Pathogenic Effector T Cells.

Authors:  Weiwei Wang; Wai Po Chong; Chunmei Li; Zilin Chen; Sihan Wu; Hongyan Zhou; Ying Wan; Wanjun Chen; Igal Gery; Yizhi Liu; Rachel R Caspi; Jun Chen
Journal:  Cell Rep       Date:  2019-07-09       Impact factor: 9.423

Review 9.  New paradigms in chemokine receptor signal transduction: Moving beyond the two-site model.

Authors:  Andrew B Kleist; Anthony E Getschman; Joshua J Ziarek; Amanda M Nevins; Pierre-Arnaud Gauthier; Andy Chevigné; Martyna Szpakowska; Brian F Volkman
Journal:  Biochem Pharmacol       Date:  2016-04-19       Impact factor: 5.858

10.  Interleukin-29: Just an extra string in the bow of Th17 cells or a target for therapeutic exploitation?

Authors:  Andrew Johnston
Journal:  J Mol Med (Berl)       Date:  2016-04       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.